Table 1.
Demographics and Outcomes of Study Sample by Gender Identity
| Demographics, per Patient | Total (N = 36 845) | Nontransgender Men (n = 27 598) | Nontransgender Women (n = 8962) | Transgender Persons (n = 285) |
|---|---|---|---|---|
| Age group at enrollmenta,b,c | ||||
| 18–29 y | 6947 (18.9) | 5100 (18.5) | 1771 (19.8) | 76 (26.6) |
| 30–39 y | 11 338 (30.8) | 8475 (30.7) | 2757 (30.8) | 106 (37.2) |
| 40–49 y | 12 391 (33.6) | 9397 (34.1) | 2916 (32.5) | 78 (27.4) |
| ≥50 y | 6169 (16.7) | 4626 (16.7) | 1518 (16.9) | 25 (8.8) |
| Race/ethnicitya,b,c | ||||
| White | 10 604 (28.8) | 9379 (34.0) | 1197 (13.4) | 37 (13.0) |
| Black | 16 715 (45.4) | 10 935 (39.6) | 5646 (63.0) | 134 (47.0) |
| Hispanic | 7973 (21.6) | 6026 (21.8) | 1848 (20.6) | 99 (34.7) |
| Other/unknown | 1553 (4.2) | 1267 (4.6) | 271 (3.0) | 15 (5.3) |
| HIV risk factora,b,c,d | ||||
| MSM | 15 848 (43.0) | 15 637 (56.7) | … | 211 (74.0) |
| HET | 12 680 (34.4) | 5937 (21.5) | 6721 (75.0) | 22 (7.7) |
| IDU | 5083 (13.8) | 3710 (13.4) | 1,346 (15.0) | 27 (9.5) |
| Other/unknown | 3234 (8.8) | 2314 (8.4) | 895 (10.0) | 25 (8.8) |
| Initial insurancea,b,c | ||||
| Private | 6173 (16.7) | 5197 (18.8) | 956 (10.7) | 20 (7.0) |
| Medicaid | 11 534 (31.3) | 7451 (27.0) | 3964 (44.2) | 119 (41.8) |
| Medicare | 3005 (8.2) | 2295 (8.3) | 685 (7.7) | 25 (8.8) |
| Ryan White/uninsured | 12 876 (35.0) | 10 367 (37.6) | 2413 (26.9) | 96 (33.6) |
| Other/unknown | 3257 (8.8) | 2288 (8.3) | 944 (10.5) | 25 (8.8) |
| CD4 count at enrollment, cells/mm3, median (IQR)a,c | 322 (113–534) | 321 (112–528) | 325 (114–553) | 335 (130–518) |
| HIV load at enrollment, log10 copies/mL, median (IQR)a,b | 3.62 (1.88–4.79) | 3.68 (1.88–4.84) | 3.51 (1.88–4.62) | 3.6 (1.70–4.68) |
| Outcomes, per Patient-Year | n = 119 826 | n = 89 163 | n = 29 806 | n = 878 |
| Retention in care, No. (%, 95% CI)e | ||||
| Retained | 86 809 (81.6, 81.3–81.8) | 64 046 (81.6, 81.3–81.9) | 22 141 (81.5, 81.0–81.9) | 622 (80.1, 77.2–82.9) |
| Not retained | 19 635 (18.4, 18.2–18.7) | 14 441 (18.4, 18.1–18.7) | 5039 (18.5, 18.1–19.0) | 155 (19.9, 17.1–22.8) |
| Received ART, No. (%, 95% CI) | ||||
| Yes | 91 937 (76.7, 76.4–76.9) | 69 379 (77.8, 77.5–78.1) | 21 891 (73.4, 72.9–73.9) | 667 (76.0, 73.1–78.8) |
| No | 27 910 (23.3, 23.0–23.5) | 19 784 (22.2, 21.9–22.5) | 7915 (26.6, 26.1–27.1) | 211 (24.0, 21.2–26.8) |
| HIV suppression, No. (%, 95% CI)f | ||||
| <400 copies/mL | 53 535 (68.0, 67.7–68.3) | 40 956 (69.7, 69.3–70.1) | 12 204 (63.1, 62.4–63.8) | 375 (68.7, 64.8–72.6) |
| ≥400 copies/mL | 25 149 (32.0, 31.6–32.3) | 17 850 (30.3, 29.9–30.7) | 7128 (36.9, 36.2–37.6) | 171 (31.3, 27.4–35.2) |
Data are No. (%) unless otherwise specified.
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HET, heterosexual transmission; HIV, human immunodeficiency virus; IDU, injection drug use; IQR, interquartile range; MSM, men who have sex with men.
a Age, race/ethnicity, HIV risk factor, and insurance were compared using the χ2 test of independence. CD4 count and HIV load were compared using the Kruskal-Wallis test due to their nonnormal distribution.
b P < .01 when comparing nontransgender men to transgender persons.
c P < .01 when comparing nontransgender women to transgender persons.
d Patients who had IDU in combination with another risk factor were categorized as injection drug users.
e Calculated for 106 440 patient years eligible for the retention in care analysis. Patients newly enrolled in care during the last 6 months of the year or who died in the first 6 months of the year were excluded.
f Calculated for 72 728 patient-years eligible for the HIV suppression analysis in which ART was prescribed for >6 months.